Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

NCT02730299 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies
Acute Lymphoblastic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Chronic Myelogenous Leukemia (CML)
Myelodysplastic Syndrome (MDS)
Lymphoma
Acute Leukemia

Interventions

DRUG: NiCord® (omidubicel)
OTHER: Cord Blood Unit

Sponsor

Gamida Cell ltd